A5762

应用筛选条件

关键词:'A5762'

显示 1-30 共 95 条结果关于 "A5762" 范围论文

Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.

Dario Ferrero et al.

Annals of hematology, 93(8), 1391-1400 (2014-04-08)

We evaluated a maintenance, post-remission treatment with low-dose chemotherapy plus differentiating agents on poor-prognosis acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) patients ineligible to allografting. Patients had either age over 60 and/or secondary AML, therapy-related AML, previous relapse, high-risk MDS. Forty-five

Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia.

Nicolas Novitzky et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 19(4), 584-588 (2012-12-29)

Immunodepletion with alemtuzumab is an effective strategy for preventing graft-versus-host disease after allogeneic stem cell transplantation (SCT), but it may be associated with graft failure. We tested the effectiveness of a purine analog-based reduced-intensity conditioning combination in patients undergoing allogeneic

Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.

Jakub Bogusz et al.

Postepy higieny i medycyny doswiadczalnej (Online), 67, 107-118 (2013-03-12)

Chronic lymphocytic leukemia (CLL) remains incurable; therefore searching for new therapeutic strategies in this disease is necessary. An important mechanism of tumor development is neoangiogenesis. A potent antiangiogenic factor, bevacizumab (Avastin, AVA), has been poorly explored in CLL so far.

Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.

Alessandro Gozzetti et al.

Leukemia research, 38(8), 891-895 (2014-06-18)

Median age at diagnosis for chronic lymphocytic leukaemia (CLL) patients is now 72 years, thus a consistent number of patients may not tolerate standard doses i.v. of fludarabine, cyclophosphamide and rituximab (FCR), the best available therapy, due to unacceptable myelotoxicity

Fludarabine: a review of the clear benefits and potential harms.

Joshua Lukenbill et al.

Leukemia research, 37(9), 986-994 (2013-06-22)

Fludarabine successfully treats chronic lymphocytic leukemia (CLL); however, its use may lead to significant myelosuppression and other toxicities. This article weighs the benefits against potential harms, highlighting strategies for appropriate patient selection and administration. Relevant studies were identified upon literature

Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.

Wolfgang Dörffel et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(12), 1562-1568 (2013-03-20)

PURPOSE To minimize the risk of late effects in pediatric Hodgkin lymphoma (HL) by omitting radiotherapy (RT) in patients in complete remission (CR) after chemotherapy and reducing the standard radiation dose to 20 Gy in patients in incomplete remission. Between

Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome.

Laura De Padua et al.

Annals of hematology, 93(7), 1261-1262 (2013-12-07)

Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.

Francesco Ceppi et al.

Journal of pediatric hematology/oncology, 36(5), e319-e321 (2014-07-01)

Posttransplant lymphoproliferative disease (PTLD) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation. We describe here the case of a boy with history of induction failure of a T-cell acute lymphoblastic leukemia, who presented a life-threatening situation of nonengraftment

Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.

Muhammad Rizwan Khawaja et al.

American journal of hematology, 90(2), 97-99 (2014-10-28)

We compared survival outcomes following myeloablative allotransplant (MAT) or cyclophosphamide/fludarabine (Cy/Flu) nonmyeloablative allotransplant (NMAT) for 165 patients with acute myelogenous leukemia (AML) in remission or without frank relapse. Patients who received NMAT were more likely to be older and have

Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.

Kavita Radhakrishnan et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 19(4), 676-677 (2013-02-14)

The effect of chemotherapy on telomere dynamics: clinical results and possible mechanisms.

Talia Diker-Cohen et al.

Leukemia & lymphoma, 54(9), 2023-2029 (2012-12-18)

Telomeres are the chromosomal end components, and their length in hematopoietic stem cells correlates with the bone marrow proliferative reserve. There are few data regarding telomere dynamics in hematopoietic stem cells after exposure to chemotherapy. We show that the attrition

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

Zhichao Liu et al.

PLoS computational biology, 7(12), e1002310-e1002310 (2011-12-24)

Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI types (hepatotoxic side effects) seen in the clinic can be translated

Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients.

Karin Garming Legert et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 22(8), 2133-2140 (2014-03-22)

Oral mucositis (OM) is a side effect of intensive chemotherapy and radiation and has been reported to affect 75-100% of hematopoietic stem cell transplantation (HSCT) recipients. The purpose of this study was to compare the incidence of OM in patients

Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein Antagonists.

Erik C Gunther et al.

Cell reports, 26(1), 145-158 (2019-01-04)

Cellular prion protein (PrPC) binds the scrapie conformation of PrP (PrPSc) and oligomeric β-amyloid peptide (Aβo) to mediate transmissible spongiform encephalopathy (TSE) and Alzheimer's disease (AD), respectively. We conducted cellular and biochemical screens for compounds blocking PrPC interaction with Aβo.

Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.

Pere Barba et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 19(4), 597-601 (2013-01-12)

Hyperferritinemia has been associated with adverse outcomes after allogeneic hematopoietic cell transplantation (allo-HCT) with myeloablative conditioning. However, its characteristics and impact on the outcome in the reduced-intensity conditioning (RIC) and in the lymphoid malignancy settings are far from clear. The

Resistin Promotes Angiogenesis in Endothelial Progenitor Cells Through Inhibition of MicroRNA206: Potential Implications for Rheumatoid Arthritis.

Chen-Ming Su et al.

Stem cells (Dayton, Ohio), 33(7), 2243-2255 (2015-04-02)

Endothelial progenitor cells (EPCs) promote angiogenesis and are therefore key contributors to a wide variety of angiogenesis-related autoimmune diseases such as rheumatoid arthritis (RA). However, the signaling mechanisms through which these progenitor cells influence RA pathogenesis remain unknown. The aim

Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.

Wenjun Zhang et al.

Medicine, 93(27), e134-e134 (2014-12-17)

This retrospective study compared efficacy and safety of fludarabine combined with intermediate-dose cytarabine (FA regimen) versus high-dose cytarabine (HiDAC regimen) as consolidation therapy in acute myeloid leukemia (AML) patients who achieved complete remission. Disease-free survival (DFS) and overall survival (OS)

Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.

Georg Hopfinger et al.

Cancer, 119(12), 2258-2267 (2013-03-21)

Scarce systematic trial data have prevented uniform therapeutic guidelines for T-cell prolymphocytic leukemia (T-PLL). A central need in this historically refractory tumor is the controlled evaluation of multiagent chemotherapy and its combination with the currently most active single agent, alemtuzumab.

Fludarabine in paediatric steroid-refractory inflammatory lung injury after stem cell transplantation.

Martine F Raphael et al.

The European respiratory journal, 41(2), 479-483 (2013-02-02)

Antiviral drug vidarabine possessing cardiac type 5 adenylyl cyclase inhibitory property did not affect cardiohemodynamic or electrophysiological variables in the halothane-anesthetized dogs

Wada T, et al.

The Journal of Toxicological Sciences, 41(1), 115-122 (2016)

Sirolimus as maintenance treatment in an infant with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia.

Maurizio Miano et al.

Journal of pediatric hematology/oncology, 36(3), e145-e148 (2013-04-17)

A 9-month-old boy with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia within the frame of a possible, undiagnosed immune-mediated disease was initially treated with prednisone. Further-line therapies of the following 7 relapses included immunoglobulins, rituximab, cyclophosphamide, and alentuzumab followed

Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).

Amandine Le Bourgeois et al.

European journal of haematology, 90(3), 177-186 (2013-01-11)

This retrospective analysis aimed to assess hematopoietic and immune recovery in a cohort of 53 patients [males: n = 33; median age: 59 yr (range: 22-70)] who received a FB2 (fludarabine 120-150 mg/m² + IV busulfan 6.4 mg/kg + antithymocyte

Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience.

S P Chantepie et al.

Leukemia research, 38(5), 569-574 (2014-03-25)

In reduced-toxicity conditioning hematopoietic stem cell transplantation, several studies failed to demonstrate the superiority of one conditioning over another. This study described 51 patients (median age of 58 years) allografted with the new FB3-ATG2 conditioning regimen for myeloid (66%) or

Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds.

P W Krug et al.

Antimicrobial agents and chemotherapy, 54(1), 452-459 (2009-10-28)

B virus infection of humans results in high morbidity and mortality in as many as 80% of identified cases. The main objective of this study was to conduct a comparative analysis of conventional and experimental antiviral drug susceptibilities of B

Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).

Brian T Hill et al.

British journal of haematology, 164(2), 297-299 (2013-10-18)

Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy.

Sho Yamazaki et al.

Internal medicine (Tokyo, Japan), 51(24), 3427-3430 (2012-12-22)

Fludarabine-based therapy is widely approved as a first-line treatment for chronic lymphocytic leukemia (CLL). This treatment is occasionally associated with prolonged myelosuppression. We herein describe the cases of CLL who underwent fludarabine, cyclophosphamide and rituximab (FCR) therapy. Bone marrow examinations

Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.

Peter Martin et al.

Cancer, 119(23), 4129-4136 (2013-09-06)

Drug choice and delivered dose of treatment potentially influence outcome in patients treated for follicular lymphoma (FL). Historically, observational studies have evaluated drug choice. The National LymphoCare Study (NLCS) is a prospective, observational study of patients with FL who were

Omega 3 fatty acids increase the chemo-sensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine.

Johannes F Fahrmann et al.

Lipids in health and disease, 12, 36-36 (2013-03-19)

B-Cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the United States. Clinical treatment of CLL is often limited due to drug resistance and severe therapy-induced toxicities. We hypothesized that the omega 3 (n-3) fatty acids

AMPK involvement in endoplasmic reticulum stress and autophagy modulation after fatty liver graft preservation: a role for melatonin and trimetazidine cocktail

Zaouali MA, et al.

Journal of Pineal Research, 55(1), 65-78 (2013)

[Fatal zygomycosis caused by Mucor indicus after haplo-identical stem cell transplantation].

Satoko Koteda et al.

[Rinsho ketsueki] The Japanese journal of clinical hematology, 54(3), 311-315 (2013-05-17)

A 62-year-old woman with acute lymphoblastic leukemia in first complete remission was treated with unrelated cord blood transplantation, but exhibited primary graft failure. She then underwent HLA-haploidentical peripheral blood stem cell transplantation from her daughter. The conditioning regimen consisted of

1/4